

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted/Updated	<i>Justification:</i>
1.	<i>Tenovus Cancer Information Centre – Change in name</i>	<i>NICE Secretariat</i>		<i>Updated</i>	<i>'Tenovus Cancer Information Centre' are now named 'Tenovus'</i>

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for the technology appraisal of trabectedin for lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

Issue date: February 2010

2.	<i>Pfizer – Incorrect comparator drug listed</i>	<i>Pfizer</i>	<i>Removed</i>	<i>Pfizer is a manufacturer of aromasin only. The matrix states that Pfizer also is a manufacturer of tamoxifen which is incorrect.</i>
3.	<i>Tamoxifen – Comparator drug listed and associated manufacturers should be removed</i>	<i>GlaxoSmithKline</i>	<i>Removed</i>	<i>It is felt that tamoxifen might not be a relevant comparator considering that the target population focused on post menopausal women in whom treatment with aromatase inhibitors would be the preferred choice of therapy (as stated in the background section of this scope)</i>
4.	<i>Confederation of Indian organisation</i>	<i>NICE Secretariat</i>	<i>Removed</i>	<i>Confederation of Indian organisation is no longer in operation</i>

National Institute for Health and Clinical Excellence

Consultation comments on the matrix for the technology appraisal of trabectedin for lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2

Issue date: February 2010